Erschienen in:
01.06.2014 | Letter to the Editor
Safety of intravenous recombinant tissue plasminogen activator in recent trauma
verfasst von:
Zabeen Mahuwala, Archana Hinduja
Erschienen in:
Acta Neurologica Belgica
|
Ausgabe 2/2014
Einloggen, um Zugang zu erhalten
Excerpt
Intravenous recombinant tissue plasminogen activator (tPA) is the only drug approved for acute ischemic stroke with a well-established safety and efficacy profile [
1]. However, the major limiting factors in using this are the narrow therapeutic window and the extensive exclusion criteria. A large number of these exclusion criteria are based on expert opinion and lack scientific basis and hence unjustifiable. Modification of the exclusion criteria could increase the rate of thrombolysis to 20 % [
2]. We report the safety of administration of intravenous tPA for acute stroke in a patient with recent pelvic fracture. …